Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
作者： Blanca D. Diez , Paul Statkevich , Yali Zhu , Malaz A. Abutarif , Fengjuan Xuan
DOI: 10.1007/S00280-009-1078-6
关键词:
摘要: Purpose Oral temozolomide is approved in many countries for malignant glioma and melanoma some outside the USA. This study evaluated exposure equivalence safety of by intravenous infusion oral administration.
springer.com
core.ac.uk
paperity.org参考文章(17)
J. Frank Jen, Population Pharmacokinetics of Temozolomide in Cancer Patients Pharmaceutical Research. ,vol. 17, pp. 1284- 1289 ,(2000) , 10.1023/A:1026403805756
Mahendra Patel, Cynthia McCully, Karen Godwin, Frank M. Balis, Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. Journal of Neuro-oncology. ,vol. 61, pp. 203- 207 ,(2003) , 10.1023/A:1022592913323
Lisa A. Hammond, John R. Eckardt, Sharyn D. Baker, S. Gail Eckhardt, Margaret Dugan, Kelly Forral, Pascale Reidenberg, Paul Statkevich, Geoffrey R. Weiss, David A. Rinaldi, Daniel D. Von Hoff, Eric K. Rowinsky, Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies Journal of Clinical Oncology. ,vol. 17, pp. 2604- 2604 ,(1999) , 10.1200/JCO.1999.17.8.2604
Christian Fizames, François Lavelle, John A. Slack, David Chubb, John A. Hickman, Robert Stone, Simon P. Langdon, Colin Goddard, Ghousia Baig, Neil W. Gibson, Edward Lunt, Christopher Newton, Malcolm F. G. Stevens, Lisa Vickers, Antitumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine Cancer Research. ,vol. 47, pp. 5846- 5852 ,(1987)
M Brada, I Judson, P Beale, S Moore, P Reidenberg, P Statkevich, M Dugan, V Batra, D Cutler, Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. British Journal of Cancer. ,vol. 81, pp. 1022- 1030 ,(1999) , 10.1038/SJ.BJC.6690802
L. Reyderman, P. Statkevich, C. M. Thonoor, J. Patrick, V. K. Batra, M. Wirth, Disposition and pharmacokinetics of temozolomide in rat Xenobiotica. ,vol. 34, pp. 487- 500 ,(2004) , 10.1080/00498250410001685737
Michelle A. Rudek, Ross C. Donehower, Paul Statkevich, Vijay K. Batra, David L. Cutler, Sharyn D. Baker, Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Pharmacotherapy. ,vol. 24, pp. 16- 25 ,(2004) , 10.1592/PHCO.24.1.16.34800
H. Bourgeois, J. Vermorken, G. Dark, A. Jones, P. Fumoleau, R. Stupp, J. Tourani, E. Brain, L. Nguyen, F. Lefresne, C. Puozzo, Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours Cancer Chemotherapy and Pharmacology. ,vol. 60, pp. 407- 413 ,(2007) , 10.1007/S00280-007-0510-Z
Tomokazu Aoki, Ryo Nishikawa, Tomohiko Mizutani, Kuniharu Nojima, Kazuhiko Mishima, Jyunichi Adachi, Masao Matsutani, Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. International Journal of Clinical Oncology. ,vol. 12, pp. 341- 349 ,(2007) , 10.1007/S10147-007-0687-5
Lincoln L. H. Tsang, Charmaine P. Quarterman, Andreas Gescher, John A. Slack, Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide web science. ,vol. 27, pp. 342- 346 ,(1991) , 10.1007/BF00688855